Company intelligence / Profile preview

Baiya Phytopharm

Ownership: Private
Employees: ~32
Development stage: Phase 1

Overview

The company's COVID-19 vaccine (Baiya SARS-CoV-2 Vax 2) has completed Phase 1 clinical trials with an acceptable safety profile, and has been recommended to continue to the second cohort. The vaccine demonstrated strong immune responses against SARS-CoV-2 and its variants in preclinical studies.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Recombinant proteinsMonoclonal antibodiesAntibody fusion proteinsVaccinesArtificial exosomes
Industry: Biotech

Drug pipeline

12 assets

Baiya SARS-CoV-2 Vax 2

11 more assets in the full pipeline.

Partnerships

PlantForm (Canada)The DABOM (South Korea)

Beyond the preview

Go deeper on Baiya Phytopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baiya Phytopharm.